US2022257551A1PendingUtilityA1

Amorphous solid form of compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations

83
Assignee: NOVARTIS PHARMACEUTICALS CORPPriority: Nov 9, 2005Filed: May 6, 2022Published: Aug 18, 2022
Est. expiryNov 9, 2025(expired)· nominal 20-yr term from priority
Inventors:Lili FengSven Erik GodtfredsenPaul Allen SuttonMahavir PrashadMichael John GirgisBin HuYugang LiuThomas J. BlacklockPiotr H. Karpinski
A61K 31/216C07D 207/50A61P 11/00A61K 31/41A61P 25/28C07C 233/47A61P 27/06A61K 45/06A61K 31/4422C07D 257/04A61P 9/06A61P 9/14A61P 9/08A61K 31/5415A61P 9/00A61P 3/10A61P 5/42A61P 27/02A61P 7/12A61P 25/06A61P 25/00A61P 9/10A61P 3/00A61K 2300/00A61P 3/06A61P 43/00A61P 3/04A61P 17/00A61P 9/12A61P 9/04A61P 13/12A61P 5/24A61P 13/02
83
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An amorphous solid form of a compound comprising of the angiotensin receptor antagonist (ARB) valsartan, the neutral endopeptidase inhibitor (NEPi) (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methylpentanoic acid ethyl ester and sodium cations is provided. This is compound is useful for the treatment of hypertension and/or heart failure.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An amorphous solid form of a compound consisting of anionic (S)-N-valeryl-N-{[ 2 ′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine, anionic (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester, and sodium cations in a 1:1:3 molar ratio. 
     
     
         2 . A pharmaceutical composition comprising the amorphous solid form according to  claim 1  and at least one pharmaceutically acceptable excipient.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.